Esperite's biotech company The Cell Factory, Belgium has received funding from the European Union's Horizon 2020 research and innovation Programme for development and characterization of the extracellular vesicles (EVs) drug CF-MEV-126 for treatment of stroke. The project is focused on the development of the 2nd generation EVs drug, with enhanced anti-inflammatory and neuroprotective activities. Amsterdam, The Netherlands -3 rd May 2018 The Cell Factory is investigating therapeutic properties of...
Amsterdam, The Netherlands - 30 April 2018 Esperite regrets to announce that due to technical issues and despite the constant efforts provided by the different teams involved, the publication of the Annual Report 2017 must be postponed until further notice. The company will communicate as soon as it is possible and expect a date before the end of May 2018. About ESPERITE ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision...
Continuation of support to Esperite's strategy, commercial activities and development of innovative technologies in the field of genetics and regenerative medicines Amsterdam, The Netherlands - 11 April 2018 As of today, EUR 5,530,000 of notes out of the total commitment amounting to EUR 9 million have been converted into shares and EUR 247,500 of warrants out of a total potential amount of EUR 4,050,000 have been exercised into shares by European Select Growth Opportunities Fund (the...
Esperite with its biotech company The Cell Factory has acquired from OPBG the full rights to the IP and the international patent family covering the invention and the therapeutic use of the EV's products. In collaboration with Women's and Children's Health Department of the University of Padua, Italy they are presenting the new generation EV's biologic drugs bio-activated with Annexin V targeting multiple inflammatory diseases i.e.: Crohn's disease, drug resistance epilepsy, stroke. The...
Amsterdam, The Netherlands - 2 March 2018 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the 16 th Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the "Notes") with a principal amount of EUR 10,000 each, with 221,893 share subscription warrants attached (the "Warrants"), under the financing agreement of up to EUR 13.0 million signed between the Group and the European Select Growth Opportunities Fund on 8 March 2017 (the...
Continuation of support to Esperite's strategy, commercial activities and development of innovative technologies in the field of genetics and regenerative medicines Amsterdam, The Netherlands - 16 February 2018 As of today, EUR 5,010,000 of notes out of the total commitment amounting to EUR 9 million have been converted into shares and EUR 247,500 of warrants out of a total potential amount of EUR 4,050,000 have been exercised into shares by European Select Growth Opportunities Fund (the...
Esperite with BGI sequencing technology will enable the global population easier access to the gold standard in clinical genetic testing. Amsterdam, The Netherlands - 31 January 2018 BGI is the world's genome sequencing center. Esperite's new partner will provide the infrastructure and the technology for massive sequencing of the Whole Genome. BGI has also processed over 10 million clinical samples, including running 2.8 million noninvasive prenatal tests, 2.6 million human papillomavirus tests,...
Amsterdam, The Netherlands - 31 January 2018 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the 14 th Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the "Notes") with a principal amount of EUR 10,000 each, with 206,801 share subscription warrants attached (the "Warrants"), under the financing agreement of up to EUR 13.0 million signed between the Group and the European Select Growth Opportunities Fund on 8 March 2017 (the...
Amsterdam, The Netherlands - 16 January 2018 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the 13 th Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the "Notes") with a principal amount of EUR 10,000 each, with 206,422 share subscription warrants attached (the "Warrants"), under the financing agreement of up to EUR 13.0 million signed between the Group and the European Select Growth Opportunities Fund on 8 March 2017 (the...
Amsterdam, The Netherlands - 10 January 2018 As Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") is completing its strategy to concentrate its laboratory activities in its state of the art and fully certified facilities in Geneva, its Belgium subsidiary company CryoSave Labs ("CSL" or the"Company") is left with no commercial activity and its facility in Neil has become redundant. Over the past months the Group has unsuccessfully looked for parties to occupy the building currently owned...
Amsterdam, The Netherlands - 10 January 2018 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the 12 th Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the "Notes") with a principal amount of EUR 10,000 each, with 206,422 share subscription warrants attached (the "Warrants"), under the financing agreement of up to EUR 13.0 million signed between the Group and the European Select Growth Opportunities Fund on 8 March 2017 (the...
Amsterdam, the Netherlands - 8 January 2018 ESPERITE N.V. (Euronext: ESP, 'ESPERITE', or 'the Group') declares the conversion of a portion of the EUR 2'025'000 loan note of CEO Frederic Amar into 1'500'000 shares as announced on 2 October 2017. CEO Frederic Amar, confident in the development of the Group, maintains his stake at a strong level after the successive dilutive issuance of shares by L1 Capital. About ESPERITE ESPERITE is a diversified biotech global group leader in regenerative and...
Amsterdam, the Netherlands - 5 January 2018 ESPERITE N.V. (Euronext: ESP, 'ESPERITE', or 'the Group') declares the issuance of a convertible loan note of EUR 400'000 to CEO Frederic Amar who has completed the additional financing announced on October 2017. This financing contributes positively to the permanent effort initiated by the management to turn around the company and to support the business development. Mr. Amar has not participated in the decision-making of the Board of Directors...
Further support of Esperite's strategy, commercial activities and development of innovative technologies in the field of genetics and regenerative medicines Amsterdam, the Netherlands - 22 December 2017 As of today, EUR 4,030,000 of notes out of the total commitment amounting to EUR 9 million have been converted into shares and EUR 247,500 of warrants out of a total potential amount of EUR 4.05 million have been exercised into shares by European Select Growth Opportunities Fund (the "Investor"),...
Esperite has taken all the necessary measures after the difficult end of the first semester. The company invests in its technology and prepares to grow again. Amsterdam, The Netherlands - 17 November 2017 Consolidated results Consolidated revenues of the period are stable despite the common slow down of activity due to the summer. The company has increased the gross margin up to 60%. EDITDA has continued to improve during the period but remains negative. Opex is reduced by 10% compared to...
Amsterdam, The Netherlands - 9 November 2017 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the Tenth Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the "Notes") with a principal amount of EUR 10,000 each under the financing agreement of up to EUR 13.0 million signed between the Group and the Investor on 8 March 2017 (the "Agreement"). In addition to the Tenth tranche, another EUR 250,000 of Notes is issued to L1 Capital under the...
Amsterdam, The Netherlands - 9 November 2017 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the Tenth Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the "Notes") with a principal amount of EUR 10,000 each under the financing agreement of up to EUR 13.0 million signed between the Group and the Investor on 8 March 2017 (the "Agreement"). In addition to the Tenth tranche, another EUR 250,000 of Notes is issued to L1 Capital under the...
Amsterdam, The Netherlands - 30 October 2017 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the Ninth Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the "Notes") with a principal amount of EUR 10,000 each, with 192,307 share subscription warrants attached (the "Warrants"), under the financing agreement of up to EUR 13.0 million signed between the Group and the Investor on 8 March 2017 (the "Agreement"). The Notes and the Warrants...
Amsterdam, The Netherlands - 10 October 2017 As of today, EUR 2,700,000 of notes out of the total commitment amounting to EUR 9 million have been converted into shares and EUR 112,500 of warrants out of a total potential amount of EUR 4.05 million have been exercised into shares by European Select Growth Opportunities Fund (the " Investor "), therefore strengthening the Group's equity. The Investor confirms its support to the development of Esperite's commercial activities and development of...
Amsterdam, The Netherlands - 10 October 2017 As of today, EUR 2,700,000 of notes out of the total commitment amounting to EUR 9 million have been converted into shares and EUR 112,500 of warrants out of a total potential amount of EUR 4.05 million have been exercised into shares by European Select Growth Opportunities Fund (the " Investor "), therefore strengthening the Group's equity. The Investor confirms its support to the development of Esperite's commercial activities and development of...